The immune landscape of esophageal cancer
TX Huang, L Fu - Cancer communications, 2019 - Springer
Esophageal cancer (EC) seriously threatens human health, and a promising new avenue for
EC treatment involves cancer immunotherapy. To improve the efficacy of EC immunotherapy …
EC treatment involves cancer immunotherapy. To improve the efficacy of EC immunotherapy …
Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis
X Cao, Y Kang, P Tai, P Zhang, X Lin, F Xu… - Clinics and Research in …, 2024 - Elsevier
Background To analyze the relationship between tumor-infiltrating lymphocytes (TILs)
subtypes and infiltration locations and the prognosis of gastric cancer (GC) patients …
subtypes and infiltration locations and the prognosis of gastric cancer (GC) patients …
High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma
G Jomrich, M Paireder, I Kristo, A Baierl… - Annals of …, 2021 - journals.lww.com
Objective: The aim of this study was to determine the clinical role of the systemic immune-
inflammation index in patients with resectable adenocarcinoma of the gastroesophageal …
inflammation index in patients with resectable adenocarcinoma of the gastroesophageal …
Immune checkpoint blockade therapy
T Wieder, T Eigentler, E Brenner, M Röcken - Journal of Allergy and Clinical …, 2018 - Elsevier
Immune checkpoints are accessory molecules that either promote or inhibit T-cell activation.
Two inhibitory molecules, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell …
Two inhibitory molecules, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell …
[HTML][HTML] Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers
Gastroesophageal cancers (GOCs) represent some of the most common cancers globally
and are linked with poor survival rates. The current standard of care includes multimodal …
and are linked with poor survival rates. The current standard of care includes multimodal …
[HTML][HTML] Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype …
AEM van Erp, YMH Versleijen-Jonkers… - Oncotarget, 2017 - ncbi.nlm.nih.gov
In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated
expression and clinical relevance of programmed cell death-1 (PD-1), programmed death …
expression and clinical relevance of programmed cell death-1 (PD-1), programmed death …
Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells
Monoclonal antibodies (abs) targeting the programmed cell death 1 (PD-1) immune
checkpoint pathway have revolutionized tumor therapy. Because T-cell-directed PD-1 …
checkpoint pathway have revolutionized tumor therapy. Because T-cell-directed PD-1 …
Immunotherapy for esophageal cancer: a 2019 update
D Schizas, N Charalampakis, C Kole, KS Mylonas… - …, 2020 - Taylor & Francis
Esophageal cancer remains a global health concern with a dismal prognosis and an
estimated 5-year survival rate of approximately 10–15%. Immunotherapy is a novel …
estimated 5-year survival rate of approximately 10–15%. Immunotherapy is a novel …
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
I Saulite, D Ignatova, YT Chang, C Fassnacht… - …, 2020 - Taylor & Francis
ABSTRACT Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell
lymphoma (L-CTCL) that arises from malignant clonally derived skin-homing CD4+ T cells …
lymphoma (L-CTCL) that arises from malignant clonally derived skin-homing CD4+ T cells …
The immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression …
T Yomoda, T Sudo, A Kawahara, T Shigaki… - Annals of Surgical …, 2019 - Springer
Background In colorectal cancer (CRC), the indication for immune checkpoint inhibitors is
determined by the microsatellite instability status of the tumors. However, an optimal …
determined by the microsatellite instability status of the tumors. However, an optimal …